On Wednesday, Civica was invited to provide comments on domestic generic drug manufacturing in a Congressional hearing titled, ‘Made in America: Restoring Trust in Our Medicines.’
“Make no mistake: low prices are the principal barrier to onshoring generic drug manufacturing. It costs millions of dollars and takes several years to bring a generic injectable drug to market. It requires a costly manufacturing facility and teams of people – R&D, manufacturing, laboratory, quality and regulatory personnel,” said Allan Coukell, Civica Chief Government Affairs and Public Policy Officer, in testimony before the U.S. Senate Special Committee on Aging. “With many injectable drugs selling for less than $1 a vial, US production simply isn’t financially viable. If we want sustainable domestic production, we must be comfortable that it is worth paying slightly more to have a safe and secure domestic industry.”
Coukell joined three other witnesses for a discussion on potential solutions to expanding domestic generic drug manufacturing:
Tom Neely, Chairman of the Board, Oxford Pharmaceuticals
Patrick Cashman, President USAntibiotics, LLC
Dr. Eric Edwards MD, PhD, CEO, PHLOW-USA
A video of the hearing can be found here: Made in America: Restoring Trust in Our … | Senate Committee On Aging (Allan Coukell’s testimony begins at 19:35)
About Civica
Founded in 2018 by innovative healthcare leaders nationwide, Civica is a pharmaceutical nonprofit dedicated to ensuring the accessibility, affordability and quality of essential generic injectables and biosimilar insulins. With 60 members, including leading health systems, hospitals, and philanthropic organizations, Civica supplies more than 70 essential medicines to over 1,400 hospitals, supporting care for over 90 million patients. By committing to long-term contracts and targeting six months of safety stock, we help stabilize the market and reduce the impact of shortages. Learn more at www.Civicarx.org.
Media Contact
Liz Power, Vice President, Communications
Liz.power@civicarx.org
860 501 3849
